61 results about "Low glucose" patented technology

In an infusion pump system that includes a pump that may have a user interface for pump programming, one or more smartphones or other remote control devices that interface with the infusion pump, and / or an automated insulin delivery algorithm, there is a potential conflict between commands such as boluses being programmed on multiple devices and / or calculated by the AID algorithm at the same time. In order to avoid low glucose levels that could result from delivering multiple boluses from these various sources when only one bolus is needed, systems and methods disclosed herein provide a bolus permissions and prioritization scheme that prioritizes boluses programmed with the infusion pump and one or more remote control devices and calculated by a closed loop delivery algorithm.

A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and / or a detected location of the user.

A system, method and non-transient computer readable medium for assessing the opportunity to address either hyperglycemic or hypoglycemic risk (or both) in patients with diabetes based on historical continuous glucose monitoring (CGM) data.

The invention belongs to the technical field of assisted reproduction, and particularly relates to a glucose slow-release structure used in an embryo in-vitro culture solution, a preparation process and a use method. The glucose slow-release structure comprises at least one inner layer containing glucose and a biodegradable material outer layer wrapping the inner layer, and the biodegradable material outer layer comprises a matrix with a plurality of micropores and at least one sealing material layer used for sealing pores of the micropores. According to the invention, gradient release from low sugar in the cleavage stage to high sugar in the blastocyst stage is realized, midway liquid change or artificial sugar supplement is not needed, the operation is obviously simplified, and pollution and mechanical stress risks are reduced.

Disclosed herein are formulations (including sweet proteins and rare sugars) for improving the sweetness of low glycemic index rare sugars without altering the texture and flavor of the rare sugars and methods for improving the sweetness of rare sugars. More specifically, the present invention discloses methods for improving the sweetness of rare sugars without altering the sweetness profile, texture and flavor of the primary sugars. The invention also discloses the addition of Brazitame protein with liquid rare sugars at different temperatures during the synthesis of the rare sugars, before crystallization or before or after caramelization of the rare sugars, to increase sweetness. The Brazilian sweet protein increases the sweetness of rare sugars, but is not limited to D-psicose, D-tagatose, D-allose, isomaltulose, trehalose, sorbose, pinose, leucobiose and the like. The invention also provides for the evaluation of non-nutritional sweeteners (such as aspartame, acesulfame, sodium cyclamate, neotame, saccharin, sucralose, stevioside, etc.), as each has a limitation of taste quality if used with rare sugars. However, the use of Brazilian sweet protein does not alter the flavor and texture of rare sugars, and the taste profile matches sucrose.

The invention belongs to the technical field of food processing, particularly relates to a low-GI high-fiber wholewheat biscuit and a preparation method thereof, and further relates to application of the low-GI high-fiber wholewheat biscuit as a low-glycemic-index food to regulation of intestinal flora. The soluble dietary fiber inulin is added into the whole wheat flour, the processing characteristics of the whole wheat flour and dough are remarkably improved through the addition of the inulin, the color and luster of the biscuit are also remarkably improved, the prepared low-GI high-fiber whole wheat biscuit has good taste and good crispness, and the content of total dietary fibers in the biscuit is as high as 19%. The GL value of the low-GI high-fiber whole-wheat biscuit is only 8.20, the GI value is 50.24, the GL value and the GI value are obviously lower than those of whole-wheat biscuits, and the low-GI high-fiber whole-wheat biscuit belongs to low-blood-sugar-load food and has a better adjusting effect on intestinal flora and short-chain fatty acid compared with the whole-wheat biscuits.

A diabetes management system optimizes glucoregulatory hormone delivery using a connected glucoregulatory hormone delivery system and a computing device with a processor and non-transitory memory. The system receives glucose management data (glucose, insulin delivery, heart rate, or carbohydrate consumption data) from sensors. A digital twin metabolic model is selected and initialized based on the received data. The system simulates diabetes treatment interventions to predict glucose dynamics and determines an optimized glucoregulatory hormone parameter (e.g., insulin dose or increment that minimizes hyperglycemia and hypoglycemia risk). The determined glucoregulatory hormone parameter is transmitted to the connected glucoregulatory hormone delivery system, which may include an automated insulin delivery (AID) system or a connected insulin pen system, for implementation. By integrating real-time physiological data with predictive metabolic modeling, the system enhances glucoregulatory hormone therapy, providing personalized adjustments to improve glucose control.

The invention relates to (Z)-5-hydroxy-3-methyl-pent-2-enamide and application thereof, in particular to a novel compound (Z)-5-hydroxy-3-methyl-pent-2-enamide extracted and separated from secondary metabolites of Fusarium acuminatum, the novel compound (Z)-5-hydroxy-3-methyl-pent-2-enamide is white powder, the molecular formula of the novel compound (Z)-5-hydroxy-3-methyl-pent-2-enamide is C6H11NO2, and a quasi-molecular ion peak given by a high-resolution mass spectrum is [2M + Na-CO] + 253.1543; the invention relates to an application of (Z)-5-hydroxy-3-methyl-pent-2-enamide in preparation of a medicine for reducing blood sugar, in particular to an application of (Z)-5-hydroxy-3-methyl-pent-2-enamide.

This invention relates to the field of beverage technology, specifically disclosing a low glycemic index health beverage rich in monk fruit leaf flavonoids. The beverage comprises main ingredients, which are composed of the following components by weight: 18-35 parts monk fruit leaf extract, 15-22 parts bitter melon extract, and 15-22 parts houttuynia cordata extract. This invention's low glycemic index health beverage, rich in monk fruit leaf flavonoids, utilizes the bioactivity of natural plant raw materials such as monk fruit leaves, bitter melon, and houttuynia cordata. Through a reasonable proportion of components, it is formulated into a compound beverage with high nutritional value, possessing health benefits such as anti-fatigue, antipyretic, anti-inflammatory, diuretic, and non-toxic effects. Furthermore, it is safe and non-toxic. Combined with monk fruit glycosides and erythritol as sweeteners, it has a good flavor while maintaining a low glycemic index, meeting the needs of people trying to reduce their sugar intake.

The invention discloses hericium erinaceus hypoglycemic peptide as well as a preparation method and application thereof. The amino acid sequence of the hericium erinaceus hypoglycemic peptide is GRVVPAPIPR. Polypeptides are extracted and purified from hericium erinaceus sporocarp protein, an amino acid sequence of one of the peptides for reducing blood sugar is determined through LC-MS / MS, the inhibition rate of the peptide for alpha-amylase is 80.63% + / -0.23% through blood sugar reduction activity detection, the inhibition rate of the peptide for alpha-glucosidase is 70.77% + / -0.29%, the peptide can be used as a natural peptide for reducing blood sugar, and the peptide for reducing blood sugar can be used as a natural peptide for reducing blood sugar. Potential application prospects are realized in the fields of preparation of medicines for reducing blood sugar and the like.

The invention provides a production method for increasing the yield of maltose, which comprises the following steps: proportioning, liquefying and saccharifying, controlling the concentration of starch milk through proportioning, reducing the concentration of syrup, improving the flowability of a system, obtaining a liquefied liquid with a low DE value in the liquefying process, and simultaneously adjusting the pH values of different reaction steps, so that the yield of maltose is increased. Finally, after saccharification is completed, the ultrahigh malt syrup which is low in content of glucose, maltose trisaccharide, maltose trisaccharide or more and high in maltose content is obtained, and the highest maltose content can reach 93%.

The invention discloses prebiotic soft fried dough twists and a making method thereof, and belongs to the technical field of food. The fried dough twist disclosed by the invention is prepared from the following raw materials in parts by mass: 132 to 169.5 parts of a dough base material, 5 to 6 parts of resistant dextrin, 7 to 9 parts of fructo-oligosaccharide microcapsules, 6 to 8 parts of isomaltitol, 1.5 to 2 parts of stachyose, 0.5 to 1.0 part of soybean lecithin and 0.01 to 0.03 part of vitamin E. The prebiotic retention rate is synergistically increased through microcapsule coating and a making process, the aging resistance of the fried dough twist is improved through synergistic moisturizing of resistant dextrin and fructo-oligosaccharide microcapsules, white granulated sugar is partially replaced by isomaltitol, stachyose and other sugar parts with low glycemic index, and the taste of the fried dough twist is improved. And the resistant dextrin with high dietary fiber content and the fructo-oligosaccharide prebiotics are matched, so that the product not only meets the sweet taste requirement, but also meets the healthy diet pursuit of modern consumers on low sugar, high fiber and high prebiotics.

This invention discloses a low glycemic index (GI) Hericium erinaceus (monkey head mushroom) steamed bun, belonging to the field of food processing and functional food applications. By weight, it is prepared from the following raw materials: 45-55 parts all-purpose flour, 28-35 parts Hericium erinaceus extract powder, 0.3-0.35 parts yeast, 15-18 parts water, 0.3-0.6 parts oil, and 0.7-0.9 parts sugar. This invention partially replaces the flour with Hericium erinaceus extract powder, fully utilizing the multiple mechanisms of action of Hericium erinaceus polysaccharides in forming a viscous gel in the digestive tract to slow down the contact between amylase and substrate, inhibiting α-amylase and α-glucosidase activity, and improving intestinal microecology and enhancing insulin sensitivity through dietary fiber. This allows the product to meet the low-GI food standard (GI<55), effectively filling the gap in low-GI steamed buns with Hericium erinaceus functional components as the core active ingredient. It has significant application value in the fields of diabetes management, weight control, and healthy staple foods.

The present invention relates to the technical field of microorganisms, in particular to a Lactobacillus acidophilus GOLDGUT-LA100 having functions of lipid lowering, blood glucose lowering and weight loss and application thereof. The Lactobacillus acidophilus GOLDGUT-LA100 provided by the present invention is preserved in China General Microbiological Culture Collection Center, with the preservation number of CGMCC No. 28398. The strain has strong acid resistance, can adapt to the digestive tract environment, and has high bile salt hydrolase activity. At the same time, in animal experiments, the strain significantly reduces blood glucose and serum cholesterol levels, reduces liver fat deposition, reduces adipose tissue inflammation, effectively reduces the weight, and has broad application prospects in the development of products for improving obesity, lowering lipid and lowering blood glucose.

The application discloses a recombinant protein, a DNA fragment, an expression vector, a preparation method of a transgenic lettuce and an oral hypoglycemic drug, relates to the technical field of biological medicines, and the amino acid sequence of the recombinant protein is shown as SEQ ID NO:1.The recombinant protein, i.e., a human transferrin-proinsulin fusion protein, can utilize the natural combination of the human transferrin-transferrin receptor to mediate the endocytosis transport of proinsulin after being orally taken, pass through the intestinal tract to enter the blood system, and reduce blood sugar.According to animal experiments, the effect of the recombinant protein is close to that of natural insulin, and the recombinant protein realizes oral delivery of insulin.

Methods of treating type 1 diabetes, improving cardiovascular health, delaying renal function decline, reducing the risk of cardiovascular death and reducing the risk of heart failure hospitalization, while minimizing adverse events such as diabetic ketoacidosis and severe hypoglycemia, using sodium-glucose cotransporter 2 (SGLT2) inhibitors are disclosed. In a preferred method, the SGLT2 inhibitor is sofogliflozin. Also disclosed are prescriptions for developing sofogliflozin and methods of administering sofogliflozin.

The invention discloses low glycemic index rice flour of a starch-fat-protein ternary complex, and relates to the technical field of food. The low-glycemic-index rice flour is prepared by mixing rice flour, lauric acid and beta lactoglobulin, the preparation process is simple and convenient to operate, the nutritional structure of traditional rice flour is optimized, the glycemic index is lower than that of the traditional rice flour, and the low-glycemic-index rice flour has good nutritional and health-care values.

A continuous glucose monitor (CGM)-driven basal insulin titration system and method for patients with Type 2 Diabetes can be adapted to the needs and concerns of subjects just starting on basal insulin therapy. The method uses as inputs historical CGM data, basal insulin dose information, reports of hypoglycemia, and past recommendations and generates an adjusted insulin dose along with a report advising whether to continue the titration process, or to stop. The method can generate a new recommendation on a regular basis (e.g., each day) until it determines an adequate, consistent dose size.

The application discloses application of a hypoglycemic peptide in preparation of a medicine for inhibiting alpha-amylase and alpha-glucosidase activity. The hypoglycemic peptide is derived from Hericium erinaceus, and the amino acid sequence is AVFPSIVGRPR. The polypeptide is extracted and purified from Hericium erinaceus fruiting body protein, the amino acid sequence of one hypoglycemic peptide is determined by LC-MS / MS, the alpha-amylase inhibition rate is 71.86%±0.08% through hypoglycemic activity detection, and the alpha-glucosidase inhibition rate is 61.52%±0.15%, so the hypoglycemic peptide can be used as a natural hypoglycemic peptide and has a potential application prospect in the field of preparation of medicines for reducing blood sugar and the like.

The application belongs to the technical field of medicine, and discloses a kind of optical compound and its preparation method and application, specifically discloses the enantiomer has different effect.In vitro experiment, enantiomer shows selectivity to target point, S-isomer tends to activate PPARγ, and R-isomer tends to activate FFAR1.In animal model, the efficacy of enantiomer also shows difference, first, two enantiomers can significantly reduce the blood sugar of animal, and significantly improve the insulin resistance of animal.However, in reducing blood triglyceride, the effect of S-isomer is obviously superior to racemate and R-isomer, and in reducing blood cholesterol, the effect of R-isomer is obviously superior to racemate and S-isomer.Therefore, (S)‑1 has important role in preparing blood sugar reducing, triglyceride reducing drug, and (R)‑1 has more significant effect in reducing blood sugar, reducing cholesterol, and has important significance for clinical targeted treatment and application.

The invention belongs to the technical field of formula foods for special medical purposes, and particularly relates to a total nutrient formula food with a low glycemic index and a preparation method thereof. The food is prepared from the following raw materials: 50 to 250 parts of concentrated whey protein powder, 40 to 150 parts of soybean protein isolate, 200 to 450 parts of fat powder, 150 to 300 parts of maltodextrin, 150 to 280 parts of cassava dextrin and 10 to 100 parts of resistant dextrin. The weight part ratio of the concentrated whey protein powder to the soybean protein isolate is (1-5): (0.8-1). According to the full-nutrition formula food with the low glycemic index, maltodextrin, cassava dextrin and resistant dextrin are specifically compounded, fructose with potential risk is abandoned, the GI value of the product is reduced to 55 or below, it is ensured that the energy supply ratio of protein, fat and carbohydrate and fatty acid composition meet the requirements of a specific dietary guide, and the low glycemic index is obtained. Unification of stable blood sugar control and comprehensive nutrition supply is realized.

The invention discloses mushroom and lucid ganoderma wine and a brewing method thereof.The mushroom and lucid ganoderma wine is prepared from 260-300 kg of rice wine, 430-470 kg of distilled liquor, 6-12 kg of mushrooms, 1-5 kg of lucid ganoderma, 2-7 kg of milkvetch roots, 2-7 kg of Chinese wolfberry fruits, 1-5 kg of mulberries, 6-12 kg of cistanche deserticola and 250-300 kg of cold boiled water according to 1000 kg of finished products. The lentinus edodes and lucid ganoderma wine brewed by the method integrates the effects of various medicinal and edible food materials such as the sticky rice, the lentinus edodes, the lucid ganoderma and the astragalus membranaceus, and has relatively high nutritional and medicinal values; the effects of resisting cancer, enhancing human immunity, tonifying qi, soothing the nerves, relieving cough and asthma, supporting healthy energy, protecting the liver, resisting fatigue, delaying senescence, reducing blood sugar, promoting circulation, expanding blood vessels, reducing blood cholesterol and triglyceride and the like can be achieved.

The invention discloses a diabetes nutrition intervention system based on a four-dimensional theory, which belongs to the field of nutrition intervention and comprises a precise nutrition intervention module, a metabolic rhythm regulation module, an intestinal flora optimization module, an emotional and lifestyle management module, a data acquisition and analysis module and a scheme regulation module. Through the synergistic effect of four dimensions of precise nutrition intervention, metabolic rhythm regulation, intestinal flora optimization and emotional and lifestyle management, the limitation of a single intervention mode is broken through, and systematic regulation of blood sugar is realized from multiple aspects of nutrition metabolism, biological clock regulation, intestinal microecological balance, physical and mental states and the like; compared with traditional single diet or exercise intervention, the insulin sensitivity can be more remarkably improved, and the blood sugar fluctuation range is reduced; according to the invention, food intervention is taken as a core, and life style adjustment is combined, so that the side effects of gastrointestinal reaction, liver and kidney function burden and the like possibly caused by long-term drug treatment are avoided.

A method for adjusting insulin comprises the steps of: an analysis apparatus acquiring carbohydrate intake data, continuous blood glucose data, and insulin administration data; the analysis apparatus determining a meal time point on the basis of the continuous blood glucose data; the analysis apparatus setting, as a pre-meal blood glucose value, a minimum blood glucose value during a preset period before the meal time point; and the analysis apparatus determining, on the basis of the pre-meal blood glucose value, the amount of insulin to be injected.

The present invention provides a low-glycemic index rice and a preparation method thereof, characterized in that the rice is tempered by adding water, first subjected to microwave treatment, then rapidly frozen, and then heated to a temperature-recovering state to obtain the low-glycemic index rice. The method of the present invention can produce a GI value of less than 55 and a starch gastrointestinal digestion rate constant of less than 0.055 min. ‑1 The product is a low-glycemic index rice, and it can better keep the original nutrients of the rice from being lost, while also maintaining the original shape and appearance quality of the rice.

The invention discloses an application of hericium erinaceus hypoglycemic peptide in preparation of a medicine for inhibiting activity of alpha-amylase and alpha-glucosidase. The amino acid sequence of the hypoglycemic peptide is AGLQFPVGR. Polypeptides are extracted and purified from hericium erinaceus sporocarp protein, an amino acid sequence of one of the peptides for reducing blood sugar is determined through LC-MS / MS, the inhibition rate of alpha-amylase is 75.82% + / -0.12% through blood sugar reduction activity detection, the inhibition rate of alpha-glucosidase is 63.33% + / -0.28%, the peptide can be used as a natural peptide for reducing blood sugar, and the peptide can be used as a natural peptide for reducing blood sugar. Potential application prospects are realized in the fields of preparation of medicines for reducing blood sugar and the like.

The invention discloses an insulin infusion control method and system based on an insulin pump, and belongs to the technical field of insulin pump control. The method comprises the steps that user basic data and user blood glucose data and motion data within a preset time period are obtained, and the obtained data are preprocessed; inputting the preprocessed multi-dimensional data into the trained blood glucose prediction model, and predicting the blood glucose change trend of the user in a period of time in the future; adjusting the basic rate of an insulin pump based on the blood glucose change trend; the system comprises a data acquisition module, a data processing module, a data analysis module and an adjustment module. By adopting the method and the system, the intelligent control model is constructed by fusing multi-dimensional data to predict the blood glucose change trend of the user, so that the insulin infusion basic rate is dynamically and accurately adjusted, the blood glucose fluctuation risk is reduced, and the treatment safety and comfort of a patient are improved.

The invention discloses a processing method of frozen minced fillet with low sweetness and low glycemic index (GI). According to the mass ratio of frozen surimi needing to be processed, 3-6% of psicose, 1-2% of oligosaccharide and 1-2% of sorbitol are subjected to ternary compounding to serve as a protein water-retaining and anti-freezing core, 0.1-0.2% of sodium tripolyphosphate, 0.1-0.2% of sodium pyrophosphate and 0.02-0.06% of sodium hexametaphosphate are compounded to provide a stable dissolution and delivery environment, the sodium hexametaphosphate and the psicose are dissolved in water to prepare a solution A, and the solution B is prepared into a solution C; sodium tripolyphosphate and sodium pyrophosphate are dissolved in water to prepare a solution B, a mixed solution of the solution A and the solution B is a low-GI buffer antifreeze agent, oligosaccharide and sorbitol are directly added, the mixture is uniformly mixed with the dehydrated surimi in a carbon dioxide refrigeration vacuum mixer, and the frozen surimi with low sweetness and low glycemic index (GI) is prepared, so that the effects of replacing cane sugar, reducing weight and improving efficiency are realized, and the quality of the surimi is improved. The freeze-resistant minced fillet has excellent freeze resistance and good gel quality, meanwhile, the sweetness is remarkably reduced, the original delicious flavor of the minced fillet is reduced, heat is reduced, sugar rising is controlled, the definite low-GI health attribute is achieved, and the healthy diet requirement of consumers can be met.

The present invention relates to a culture medium comprising low glucose DMEM, L- glutamine, foetal bovine serum (FBS), antimicrobials and a trypsin inhibitor; the use of said culture medium for culturing mammalian cells and / or maintaining the viability of live tissue or tumour slices, optionally in a perfusion model; a method for 5 identifying a treatment for cancer utilising said culture medium; and a method for perfusion cell culture utilising said culture medium.

Provided are methods for treating patients with type 1 diabetes, wherein the patient has new onset type 1 diabetes no more than eight months before starting treatment, and has not previously received an immunomodulatory agent. Also provided are methods for improving cell health in a patient having type 1 diabetes. Also provided are methods for preserving residual C-peptide in a patient having type 1 diabetes. The methods comprise administering an effective amount of a pharmaceutical therapy that comprises eflornithine while the patient is maintained on a low polyamine diet, wherein the method prevents, delays, decreases the likelihood of, or decreases the severity of diabetic ketoacidosis severe hypoglycemia, progression of diabetic nephropathy and retinopathy.